share_log

CVRx, Inc. (NASDAQ:CVRX) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny

CVRx, Inc. (NASDAQ:CVRX) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny

CVRx公司(納斯達克股票代號:CVRX)股票暴跌27%,看似有機會,但需要再仔細覈查。
Simply Wall St ·  06/04 18:25

Unfortunately for some shareholders, the CVRx, Inc. (NASDAQ:CVRX) share price has dived 27% in the last thirty days, prolonging recent pain.    The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 46% in that time.  

不幸的是,對於一些股東而言,CVRx股份有限公司(NASDAQ:CVRX)的股價在過去30天下跌了27%,延長了最近的痛苦。在過去的一年中,股價下跌了46%,這一下跌趨勢在過去30天的跌勢結束。

Although its price has dipped substantially, you could still be forgiven for feeling indifferent about CVRx's P/S ratio of 3.4x, since the median price-to-sales (or "P/S") ratio for the Medical Equipment industry in the United States is also close to 3.2x.  Although, it's not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.    

儘管CVRx的股價已大幅下跌,但其3.4倍的市銷率並不會讓你感到漠不關心。美國醫療設備行業的中位數市銷率也接近3.2倍。儘管如此,不明確解釋市銷比例並不明智,因爲投資者可能會忽略一個獨特的機會或代價昂貴的錯誤。

NasdaqGS:CVRX Price to Sales Ratio vs Industry June 4th 2024

納斯達克:CVRX市銷率與行業相比 2024年6月4日

How Has CVRx Performed Recently?

CVRx最近的表現如何?

With revenue growth that's superior to most other companies of late, CVRx has been doing relatively well.   Perhaps the market is expecting this level of performance to taper off, keeping the P/S from soaring.  If the company manages to stay the course, then investors should be rewarded with a share price that matches its revenue figures.    

由於最近營收增長表現優異,CVRx的表現相對不錯。也許市場預計這種表現水平會減退,從而避免市銷率飆升。如果公司能夠繼續保持這種表現,那麼投資者應該會獲得與其營收符合的股價回報。

Want the full picture on analyst estimates for the company? Then our free report on CVRx will help you uncover what's on the horizon.  

想得到有關本公司分析師預測的完整圖景嗎?那麼我們對CVRx的免費報告將幫助您揭示未來的走勢。

How Is CVRx's Revenue Growth Trending?  

CVRx的營收增長趨勢如何?

CVRx's P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.  

CVRx的市銷率適合預計僅實現中等增長,並且重要的是能夠與行業保持一致的公司。

If we review the last year of revenue growth, the company posted a terrific increase of 60%.   Spectacularly, three year revenue growth has ballooned by several orders of magnitude, thanks in part to the last 12 months of revenue growth.  Therefore, it's fair to say the revenue growth recently has been superb for the company.  

如果回顧去年的營收增長情況,該公司的營收增長比大多數其他公司都高了60%。值得注意的是,由於在過去12個月中營收增長,三年營收增長已經大幅增加了幾個數量級。因此,最近該公司的營收增長表現非常出色。

Shifting to the future, estimates from the six analysts covering the company suggest revenue should grow by 33% per annum over the next three years.  That's shaping up to be materially higher than the 11% each year growth forecast for the broader industry.

轉向未來,覆蓋該公司的六位分析師的估計顯示,未來三年該公司的收入每年將增長33%。這將顯着高於更廣泛行業11%的年增長預測。

In light of this, it's curious that CVRx's P/S sits in line with the majority of other companies.  It may be that most investors aren't convinced the company can achieve future growth expectations.  

鑑於此,讓人好奇的是,CVRx的市銷率與其他大多數公司相當。可能是大多數投資者不確定該公司能否實現未來的增長預期。

What We Can Learn From CVRx's P/S?

我們從CVRx的市銷率中可以學到什麼?

CVRx's plummeting stock price has brought its P/S back to a similar region as the rest of the industry.      While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.

CVRx不斷下跌的股價已經讓其市銷比率回到了行業的相似水平。儘管市銷比率不應該是購買股票的決定性因素,但它是收入預期的相當可靠的指標。

Despite enticing revenue growth figures that outpace the industry, CVRx's P/S isn't quite what we'd expect.  There could be some risks that the market is pricing in, which is preventing the P/S ratio from matching the positive outlook.  However, if you agree with the analysts' forecasts, you may be able to pick up the stock at an attractive price.    

儘管CVRx的收入增長數據非常吸引人,超過了行業水平,但市銷比率並不如我們預期那樣。市場可能正在定價一些風險,這會使市銷比率無法與積極前景相匹配。但是,如果您同意分析師的預測,您可能可以以有利的價格購買股票。

Having said that, be aware  CVRx is showing 3 warning signs in our investment analysis, you should know about.  

話雖如此,請注意,CVRx在我們的投資分析中顯示出了3個警示信號,您應該知道。

If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

如果過去穩定的盈利增長公司符合您的口味,您可能希望查看這些具有強勁盈利增長和低市盈率的其他公司的免費集合。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關注內容?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論